Millipore Sigma Vibrant Logo

504712 β-Catenin/Tcf Inhibitor VI, ICG-001 - CAS 847591-62-2 - Calbiochem

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: (6S,9aS)-Hexahydro-6-((4-hydroxyphenyl)methyl)-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S)-N-Benzyl-6-(p-hydroxyphenylmethyl)-8-(1-naphthylmethyl)-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, ICG001, Wnt Pathway Inhibitor XX

Primary Target: CREB-binding protein
View Products on Sigmaaldrich.com
504712
View Pricing & Availability

Overview

Replacement Information

Key Specifications Table

CAS #Empirical Formula
847591-62-2C₃₃H₃₂N₄O₄

Pricing & Availability

Catalog Number AvailabilityPackaging Qty/Pack Price Quantity
5.04712.0001
Retrieving availability...
—
Limited Availability Limited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Glass bottle 10 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable pyrazinopyrimidinecarboxamide that competes against β-catenin for CBP (CREB-binding protein) binding and selectively prevents CBP- but not p300-, dependent TCF/β-catenin transcriptional regulations both in cultures in vitro (5 to 25 µM) and in mice in vivo (5 mg/kg/day via osmotic pump infusion), while not affecting CBP-dependent transcriptional activities mediated by the AP-1 or CRE complex. Shown to reactivate p300//TCF/β-catenin-mediated neuronal differentiation upon NGF stimulation in PS-1 L286V mutant-expressing PC-12 cultures and be efficacious in alleviating bleomycin- (0,08 units/50 µL/mouse; administered intranasally; Cat. No. 203401) induced pulmonary fibrosis in mice.
      Catalogue Number504712
      Brand Family Calbiochem®
      Synonyms(6S,9aS)-Hexahydro-6-((4-hydroxyphenyl)methyl)-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S)-N-Benzyl-6-(p-hydroxyphenylmethyl)-8-(1-naphthylmethyl)-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, ICG001, Wnt Pathway Inhibitor XX
      References
      ReferencesYan, D., et al. 2012. J. Biol. Chem. 287, 8598.
      Henderson, W.R. Jr, et al. 2010. Proc. Natl. Acad. Sci. USA. 107, 14309.
      Eguchi, M., et al. 2005. Med Chem. 1, 467.
      Ma, H., et al. 2005. Oncogene. 24, 3619.
      Teo, J.L., et al. 2005. Proc. Natl. Acad. Sci. USA. 102, 12171.
      Emami, K.H., et al. 2004. Proc. Natl. Acad. Sci. USA. 101, 12682.
      Product Information
      CAS number847591-62-2
      FormOff-white powder
      Hill FormulaC₃₃H₃₂N₄O₄
      Chemical formulaC₃₃H₃₂N₄O₄
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetCREB-binding protein
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalog Number GTIN
      5.04712.0001 04055977244052

      Documentation

      β-Catenin/Tcf Inhibitor VI, ICG-001 - CAS 847591-62-2 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      References

      Reference overview
      Yan, D., et al. 2012. J. Biol. Chem. 287, 8598.
      Henderson, W.R. Jr, et al. 2010. Proc. Natl. Acad. Sci. USA. 107, 14309.
      Eguchi, M., et al. 2005. Med Chem. 1, 467.
      Ma, H., et al. 2005. Oncogene. 24, 3619.
      Teo, J.L., et al. 2005. Proc. Natl. Acad. Sci. USA. 102, 12171.
      Emami, K.H., et al. 2004. Proc. Natl. Acad. Sci. USA. 101, 12682.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision26-July-2013 JSW
      Synonyms(6S,9aS)-Hexahydro-6-((4-hydroxyphenyl)methyl)-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide, (6S)-N-Benzyl-6-(p-hydroxyphenylmethyl)-8-(1-naphthylmethyl)-4,7-dioxohexahydro-2H-pyrazino[1,2-a]pyrimidine-1-carboxamide, ICG001, Wnt Pathway Inhibitor XX
      DescriptionA cell-permeable pyrazinopyrimidinecarboxamide that competes against β-catenin for CBP (CREB-binding protein) binding (5 to 10 µM for 24 h in SW480 and C2C12 cultures) and selectively prevents CBP- but not p300-, dependent TCF/β-catenin transcriptional regulations both in cultures in vitro (5 to 25 µM in SW480, HCT116, rat RLT-6TN, and primary human IPF lung fibroblasts; 4 to 24 h) and in mice in vivo (5 mg/kg/day via osmotic pump infusion), while not affecting CBP-dependent transcriptional activities mediated by the AP-1 or CRE complex. Selective blockage of CBP/TCF/β-catenin complex formation by ICG-001 is shown to reactivate p300//TCF/β-catenin-mediated neuronal differentiation upon NGF stimulation in PS-1 L286V mutant-expressing PC-12 cultures (cell population with neurite outgrowth = 90% and 17% of wt PS-1 control level, respectively, with or without 10 µM ICG-001) and be efficacious in alleviating bleomycin- (0,08 units/50 µL/mouse; administered intranasally; Cat. No. 203401) induced pulmonary fibrosis in mice (5 mg/kg/day via osmotic pump infusion; 10 d treatment starting 1 d before bleomycin induction or 21 d treatment starting d 21 post bleomycin induction).
      FormOff-white powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number847591-62-2
      Chemical formulaC₃₃H₃₂N₄O₄
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (100 mg/ml). Use only fresh DMSO for reconstitution.
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesYan, D., et al. 2012. J. Biol. Chem. 287, 8598.
      Henderson, W.R. Jr, et al. 2010. Proc. Natl. Acad. Sci. USA. 107, 14309.
      Eguchi, M., et al. 2005. Med Chem. 1, 467.
      Ma, H., et al. 2005. Oncogene. 24, 3619.
      Teo, J.L., et al. 2005. Proc. Natl. Acad. Sci. USA. 102, 12171.
      Emami, K.H., et al. 2004. Proc. Natl. Acad. Sci. USA. 101, 12682.